Mosaic ImmunoEngineering Inc. (CPMV)
USD 0.65
(-22.25%)
USD 0.65
(-22.25%)
| Year | Operating Income | Operating Income Growth |
|---|---|---|
| 2022 | -2.62 Million USD | 28.23% |
| 2021 | -3.66 Million USD | 0.0% |
| 2019 | -734.06 Thousand USD | 0.0% |
| 2017 | -1.04 Million USD | 13.91% |
| 2016 | -1.21 Million USD | 22.84% |
| 2015 | -1.57 Million USD | -9.64% |
| 2014 | -1.43 Million USD | 13.39% |
| 2013 | -1.66 Million USD | -20.17% |
| 2012 | -1.38 Million USD | 30.75% |
| 2011 | -1.99 Million USD | 69.02% |
| 2010 | -6.43 Million USD | 49.55% |
| 2009 | -12.76 Million USD | -81.31% |
| 2008 | -7.03 Million USD | -25.63% |
| 2007 | -5.6 Million USD | 62.05% |
| 2006 | -14.76 Million USD | -477.43% |
| 2005 | 3.91 Million USD | 4374.49% |
| 2004 | 87.42 Thousand USD | 105.03% |
| 2003 | -1.73 Million USD | 28.79% |
| 2002 | -2.43 Million USD | 40.72% |
| 2001 | -4.11 Million USD | 17.91% |
| 2000 | -5.01 Million USD | -70.54% |
| 1999 | -2.94 Million USD | 21.41% |
| 1998 | -3.74 Million USD | -12.02% |
| 1997 | -3.33 Million USD | -16.77% |
| 1996 | -2.86 Million USD | -20.26% |
| 1995 | -2.37 Million USD | 0.0% |
| Year | Operating Income | Operating Income Growth |
|---|---|---|
| 2023 Q3 | -311.87 Thousand USD | 11.53% |
| 2023 Q1 | -459.77 Thousand USD | 7.59% |
| 2023 Q2 | -352.5 Thousand USD | 23.33% |
| 2022 Q4 | -497.55 Thousand USD | 3.8% |
| 2022 Q2 | -883.72 Thousand USD | -21.22% |
| 2022 Q3 | -517.2 Thousand USD | 41.47% |
| 2022 Q1 | -729.03 Thousand USD | 11.63% |
| 2022 FY | -2.62 Million USD | 28.23% |
| 2021 FY | -3.66 Million USD | 0.0% |
| 2021 Q1 | -804.43 Thousand USD | -27.81% |
| 2021 Q2 | -910.7 Thousand USD | -13.21% |
| 2021 Q3 | -961.05 Thousand USD | -5.53% |
| 2021 Q4 | -824.95 Thousand USD | 14.16% |
| 2020 Q4 | -629.38 Thousand USD | -443.27% |
| 2020 Q2 | -101.7 Thousand USD | 2.05% |
| 2020 Q1 | -103.83 Thousand USD | 78.7% |
| 2020 Q3 | -115.85 Thousand USD | -13.91% |
| 2019 Q4 | -487.44 Thousand USD | -60.85% |
| 2019 FY | -734.06 Thousand USD | 0.0% |
| 2019 Q1 | -158.62 Thousand USD | -10.21% |
| 2019 Q2 | -228.03 Thousand USD | -43.76% |
| 2019 Q3 | -303.03 Thousand USD | -32.89% |
| 2018 Q3 | -203.48 Thousand USD | 13.65% |
| 2018 Q1 | -274 Thousand USD | -7.81% |
| 2018 Q2 | -235.64 Thousand USD | 14.0% |
| 2018 Q4 | -143.92 Thousand USD | 29.27% |
| 2017 Q2 | -328.46 Thousand USD | -16.78% |
| 2017 FY | -1.04 Million USD | 13.91% |
| 2017 Q1 | -281.26 Thousand USD | 1.05% |
| 2017 Q3 | -283.32 Thousand USD | 13.74% |
| 2017 Q4 | -254.15 Thousand USD | 10.29% |
| 2016 Q4 | -284.24 Thousand USD | 11.83% |
| 2016 Q3 | -322.37 Thousand USD | 25.18% |
| 2016 Q1 | -405.24 Thousand USD | -18.42% |
| 2016 Q2 | -430.86 Thousand USD | -6.32% |
| 2016 FY | -1.21 Million USD | 22.84% |
| 2015 FY | -1.57 Million USD | -9.64% |
| 2015 Q4 | -342.19 Thousand USD | 14.06% |
| 2015 Q3 | -398.16 Thousand USD | 13.47% |
| 2015 Q2 | -460.13 Thousand USD | -85.79% |
| 2015 Q1 | -247.66 Thousand USD | 30.7% |
| 2014 FY | -1.43 Million USD | 13.39% |
| 2014 Q1 | -379 Thousand USD | -1.48% |
| 2014 Q2 | -468.94 Thousand USD | -23.73% |
| 2014 Q3 | -372.62 Thousand USD | 20.54% |
| 2014 Q4 | -357.37 Thousand USD | 4.09% |
| 2013 FY | -1.66 Million USD | -20.17% |
| 2013 Q4 | -373.49 Thousand USD | 14.86% |
| 2013 Q3 | -438.65 Thousand USD | -8.02% |
| 2013 Q2 | -406.08 Thousand USD | -17.67% |
| 2013 Q1 | -345.11 Thousand USD | -44.9% |
| 2012 FY | -1.38 Million USD | 30.75% |
| 2012 Q1 | -681.08 Thousand USD | 12.83% |
| 2012 Q4 | -238.17 Thousand USD | 39.25% |
| 2012 Q2 | -1.37 Million USD | -101.32% |
| 2012 Q3 | -392.06 Thousand USD | 71.41% |
| 2011 Q3 | -805.22 Thousand USD | 62.5% |
| 2011 Q2 | -2.14 Million USD | -122.38% |
| 2011 Q1 | -965.46 Thousand USD | 44.58% |
| 2011 FY | -1.99 Million USD | 69.02% |
| 2011 Q4 | -781.29 Thousand USD | 2.97% |
| 2010 Q1 | -1.52 Million USD | 79.32% |
| 2010 Q2 | -1.5 Million USD | 1.38% |
| 2010 FY | -6.43 Million USD | 49.55% |
| 2010 Q3 | -1.58 Million USD | -5.61% |
| 2010 Q4 | -1.74 Million USD | -9.94% |
| 2009 Q2 | -2.71 Million USD | -64.97% |
| 2009 Q3 | -2.38 Million USD | 12.08% |
| 2009 Q4 | -7.35 Million USD | -208.71% |
| 2009 FY | -12.76 Million USD | -81.31% |
| 2009 Q1 | -1.64 Million USD | -7.46% |
| 2008 Q1 | -1.32 Million USD | 25.76% |
| 2008 Q3 | -1.15 Million USD | -32.31% |
| 2008 FY | -7.03 Million USD | -25.63% |
| 2008 Q2 | -873.98 Thousand USD | 34.07% |
| 2008 Q4 | -1.52 Million USD | -32.24% |
| 2007 Q1 | -1.72 Million USD | 78.45% |
| 2007 FY | -5.6 Million USD | 62.05% |
| 2007 Q3 | -1.61 Million USD | 29.99% |
| 2007 Q2 | -2.31 Million USD | -33.78% |
| 2007 Q4 | -1.78 Million USD | -10.33% |
| 2006 Q1 | 58.05 Million USD | 3469.19% |
| 2006 Q3 | -2.7 Million USD | 95.24% |
| 2006 Q2 | -56.8 Million USD | -197.86% |
| 2006 FY | -14.76 Million USD | -477.43% |
| 2006 Q4 | -8.01 Million USD | -196.29% |
| 2005 FY | 3.91 Million USD | 4374.49% |
| 2005 Q2 | -790.9 Thousand USD | -143.64% |
| 2005 Q3 | 4.39 Million USD | 655.13% |
| 2005 Q1 | 1.81 Million USD | 523.6% |
| 2005 Q4 | -1.72 Million USD | -139.24% |
| 2004 Q2 | -439.27 Thousand USD | -5.41% |
| 2004 Q3 | -506.15 Thousand USD | -15.23% |
| 2004 FY | 87.42 Thousand USD | 105.03% |
| 2004 Q1 | -416.71 Thousand USD | -8.01% |
| 2004 Q4 | -427.84 Thousand USD | 15.47% |
| 2003 Q3 | -495.56 Thousand USD | 4.77% |
| 2003 Q2 | -520.38 Thousand USD | -1.07% |
| 2003 Q1 | -514.88 Thousand USD | 30.73% |
| 2003 FY | -1.73 Million USD | 28.79% |
| 2003 Q4 | -385.82 Thousand USD | 22.15% |
| 2002 Q1 | -964.7 Thousand USD | 25.37% |
| 2002 FY | -2.43 Million USD | 40.72% |
| 2002 Q4 | -743.27 Thousand USD | -12.38% |
| 2002 Q3 | -661.4 Thousand USD | 19.31% |
| 2002 Q2 | -819.68 Thousand USD | 15.03% |
| 2001 FY | -4.11 Million USD | 17.91% |
| 2001 Q1 | -1.36 Million USD | -13.58% |
| 2001 Q4 | -1.29 Million USD | -24.38% |
| 2001 Q3 | -1.03 Million USD | 32.79% |
| 2001 Q2 | -1.54 Million USD | -13.27% |
| 2000 FY | -5.01 Million USD | -70.54% |
| 2000 Q4 | -1.2 Million USD | -33.49% |
| 2000 Q3 | -900.41 Thousand USD | -8.65% |
| 2000 Q1 | -879.86 Thousand USD | -67.67% |
| 2000 Q2 | -828.76 Thousand USD | 5.81% |
| 1999 Q4 | -524.75 Thousand USD | 25.75% |
| 1999 Q3 | -706.7 Thousand USD | 0.0% |
| 1999 FY | -2.94 Million USD | 21.41% |
| 1998 FY | -3.74 Million USD | -12.02% |
| 1997 FY | -3.33 Million USD | -16.77% |
| 1996 FY | -2.86 Million USD | -20.26% |
| 1995 FY | -2.37 Million USD | 0.0% |
| Name | Operating Income | Operating Income Difference |
|---|---|---|
| Burzynski Research Institute, Inc. | -1.33 Million USD | -96.755% |
| Arch Therapeutics, Inc. | -5.04 Million USD | 47.913% |
| Evofem Biosciences, Inc. | -17.84 Million USD | 85.278% |
| Nascent Biotech, Inc. | -2.22 Million USD | -17.832% |
| Rebus Holdings, Inc. | -664 Thousand USD | -295.711% |
| Santhera Pharmaceuticals Holding AG | 81.85 Million USD | 103.21% |
| Qrons Inc. | -643.67 Thousand USD | -308.205% |
| Adynxx, Inc. | - USD | Infinity% |
| Neon Bloom, Inc. | -389.57 Thousand USD | -574.467% |
| Northwest Biotherapeutics, Inc. | -55.5 Million USD | 95.266% |
| ProtoKinetix, Incorporated | -415.47 Thousand USD | -532.408% |
| Skye Bioscience, Inc. | -13.67 Million USD | 80.781% |
| Eiger BioPharmaceuticals, Inc. | -71.78 Million USD | 96.34% |
| Nanobac Pharmaceuticals, Incorporated | 4.91 Million USD | 153.461% |
| Institute of Biomedical Research Corp. | -261.72 Thousand USD | -903.921% |
| SQZ Biotechnologies Company | -75.82 Million USD | 96.535% |
| Intellipharmaceutics International Inc. | -2.85 Million USD | 7.823% |
| Propanc Biopharma, Inc. | -1.53 Million USD | -71.057% |
| Mesoblast Limited | -84.14 Million USD | 96.877% |
| Marizyme, Inc. | -34.08 Million USD | 92.292% |
| Genus plc | 6.4 Million USD | 141.055% |
| VioQuest Pharmaceuticals, Inc. | 9.74 Million USD | 126.97% |
| Pharming Group N.V. | -4.87 Million USD | 46.152% |
| Therapeutic Solutions International, Inc. | -1.98 Million USD | -32.27% |
| CNBX Pharmaceuticals Inc. | -931.38 Thousand USD | -182.111% |
| Nymox Pharmaceutical Corporation | -8.35 Million USD | 68.533% |
| ContraFect Corporation | -56.88 Million USD | 95.381% |
| PsyBio Therapeutics Corp. | -4.55 Million USD | 42.312% |
| Sienna Biopharmaceuticals, Inc. | - USD | Infinity% |
| RegeneRx Biopharmaceuticals, Inc. | -1.4 Million USD | -87.414% |
| IMV Inc. | -38.67 Million USD | 93.206% |
| AXIM Biotechnologies, Inc. | -2.75 Million USD | 4.483% |
| MultiCell Technologies, Inc. | -722.81 USD | -363414.893% |
| ONE Bio Corp. | 13.68 Million USD | 119.205% |
| Accustem Sciences Inc. | -3.74 Million USD | 29.866% |
| RVL Pharmaceuticals plc | -58.99 Million USD | 95.546% |
| Arno Therapeutics, Inc. | - USD | Infinity% |
| EV Biologics, Inc. | -483.06 Thousand USD | -443.931% |
| Q BioMed Inc. | -3.44 Million USD | 23.743% |
| Emmaus Life Sciences, Inc. | 3.54 Million USD | 174.224% |
| Biomind Labs Inc. | -1 Million USD | -160.253% |
| American Oriental Bioengineering, Inc. | -54.97 Million USD | 95.22% |
| Provectus Biopharmaceuticals, Inc. | -2.9 Million USD | 9.435% |
| TetraLogic Pharmaceuticals Corporation | - USD | Infinity% |
| Oncotelic Therapeutics, Inc. | -6.64 Million USD | 60.477% |
| GlobeStar Therapeutics Corporation | -1.86 Million USD | -40.934% |
| THC Farmaceuticals, Inc. | -29.95 Thousand USD | -8672.443% |
| Acro Biomedical Co., Ltd. | -15.86 Million USD | 83.443% |
| Curative Biotechnology, Inc. | -1.93 Million USD | -35.957% |
| GB Sciences, Inc. | -1.42 Million USD | -84.97% |
| Alpha Cognition Inc. | -9.7 Million USD | 72.928% |
| HST Global, Inc. | -140.9 Thousand USD | -1764.721% |
| CSL Limited | 3.7 Billion USD | 100.071% |
| Wesana Health Holdings Inc. | -1.12 Million USD | -133.577% |
| Halberd Corporation | -75.05 Thousand USD | -3401.029% |
| Enzolytics Inc. | -2.14 Million USD | -22.279% |
| Agentix Corp. | -1.37 Million USD | -91.544% |
| Resverlogix Corp. | -12.74 Million USD | 79.39% |
| Nuo Therapeutics, Inc. | -3.16 Million USD | 17.068% |
| MetaStat, Inc. | - USD | Infinity% |
| argenx SE | -425.04 Million USD | 99.382% |
| Enzon Pharmaceuticals, Inc. | -1.04 Million USD | -151.678% |
| Endonovo Therapeutics, Inc. | -2.91 Million USD | 9.999% |
| RespireRx Pharmaceuticals Inc. | -1.57 Million USD | -66.367% |
| GeneThera, Inc. | - USD | Infinity% |
| Inhibitor Therapeutics, Inc. | -3.4 Million USD | 22.833% |
| AVAX Technologies, Inc. | 6.69 Million USD | 139.258% |
| Zenith Capital Corp. | -8.94 Million USD | 70.619% |
| Genscript Biotech Corporation | -415.79 Million USD | 99.368% |
| Ember Therapeutics, Inc. | -17.42 Thousand USD | -14982.498% |
| Anthera Pharmaceuticals, Inc. | - USD | Infinity% |
| Sigyn Therapeutics, Inc. | -2.45 Million USD | -7.014% |
| WPD Pharmaceuticals Inc. | -171.5 Thousand USD | -1431.998% |
| Cotinga Pharmaceuticals Inc. | -2 Million USD | -31.064% |
| Kadimastem Ltd | -3.04 Million USD | 13.575% |
| Helix BioMedix, Inc. | -984.05 Thousand USD | -167.01% |
| VitaSpring Biomedical Co. Ltd. | - USD | Infinity% |
| Capstone Therapeutics Corp. | -1.25 Million USD | -109.198% |
| BioStem Technologies, Inc. | -7.77 Million USD | 66.223% |
| Oncology Pharma Inc. | - USD | Infinity% |
| Reve Technologies, Inc. | -181.48 Thousand USD | -1347.79% |
| LadRx Corporation | -3.82 Million USD | 31.282% |
| Cell Source, Inc. | -4.32 Million USD | 39.253% |
| Regen BioPharma, Inc. | -686.95 Thousand USD | -282.491% |
| Regen BioPharma, Inc. | -686.95 Thousand USD | -282.491% |
| NovAccess Global Inc. | -2.46 Million USD | -6.517% |
| Affymax, Inc. | -15.04 Million USD | 82.537% |
| Itoco Inc. | -919.14 Thousand USD | -185.867% |
| Rasna Therapeutics, Inc. | -4.23 Million USD | 38.007% |
| Pathfinder Cell Therapy, Inc. | -1.11 Million USD | -134.81% |
| Mobile Lads Corp. | -554.55 Thousand USD | -373.812% |
| CytoDyn Inc. | -18.05 Million USD | 85.45% |
| Claritas Pharmaceuticals, Inc. | - USD | Infinity% |
| NDT Pharmaceuticals Inc. | -25.17 Thousand USD | -10339.102% |
| NanoSphere Health Sciences Inc. | -220.07 Thousand USD | -1093.905% |
| Alseres Pharmaceuticals, Inc. | -564.72 Thousand USD | -365.276% |
| SYBLEU INC | -149.18 Thousand USD | -1661.31% |
| Advanced Proteome Therapeutics Corporation | - USD | Infinity% |
| ImmunoCellular Therapeutics, Ltd. | -1.81 Million USD | -44.662% |
| International Stem Cell Corporation | -663 Thousand USD | -296.308% |
| Bioxytran, Inc. | -3.82 Million USD | 31.219% |
| GlobeImmune, Inc. | - USD | Infinity% |
| Predictive Technology Group, Inc. | - USD | Infinity% |
| ProText Mobility, Inc. | -52.64 Thousand USD | -4891.493% |
| Cardax, Inc. | - USD | Infinity% |
| VG Life Sciences Inc. | -20.34 Thousand USD | -12818.004% |
| Kaleido Biosciences, Inc. | - USD | Infinity% |
| Advaxis, Inc. | -36.26 Million USD | 92.755% |
| Adhera Therapeutics, Inc. | -1.61 Million USD | -62.393% |
| RenovaCare, Inc. | - USD | Infinity% |
| Regnum Corp. | -735.83 Thousand USD | -257.08% |
| Innovation Pharmaceuticals Inc. | -3.11 Million USD | 15.541% |
| Neutra Corp. | -229.48 Thousand USD | -1044.96% |
| Windtree Therapeutics, Inc. | -17.53 Million USD | 85.019% |
| PureTech Health plc | -146.19 Million USD | 98.203% |
| Coeptis Therapeutics, Inc. | -21.49 Million USD | 87.774% |
| IXICO plc | -1.43 Million USD | -82.848% |
| IntelGenx Technologies Corp. | -9.49 Million USD | 72.316% |
| Gelesis Holdings, Inc. | -121.8 Million USD | 97.843% |
| CSL Limited | 3.81 Billion USD | 100.069% |
| Cellectis S.A. | -108.85 Million USD | 97.586% |